Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
132.52%
RETURN ON EQUITY (ROE) AVG 3Y
70.84%
RETURN ON EQUITY (ROE) AVG 5Y
62.85%
RETURN ON EQUITY (ROE) AVG 10Y
83.73%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
AbbVie Inc.
Market Cap
$439.68B
Return on Equity (ROE)
N/A
TTM Avg
132.52%
3Y Avg
70.84%
5Y Avg
62.85%
Market Cap
$366.74B
Return on Equity (ROE)
7.57%
TTM Avg
35.83%
3Y Avg
26.05%
5Y Avg
27.71%
Market Cap
$364.02B
Return on Equity (ROE)
14.34%
TTM Avg
14.18%
3Y Avg
19.86%
5Y Avg
21.18%
Market Cap
$344.74B
Return on Equity (ROE)
38.06%
TTM Avg
32.06%
3Y Avg
36.93%
5Y Avg
40.66%
Market Cap
$248.20B
Return on Equity (ROE)
20.79%
TTM Avg
19.16%
3Y Avg
15.60%
5Y Avg
13.86%
Market Cap
$648.55B
Return on Equity (ROE)
24.76%
TTM Avg
26.27%
3Y Avg
31.76%
5Y Avg
29.75%
Market Cap
$224.09B
Return on Equity (ROE)
13.25%
TTM Avg
12.70%
3Y Avg
13.51%
5Y Avg
15.24%
Market Cap
$212.20B
Return on Equity (ROE)
74.80%
TTM Avg
79.33%
3Y Avg
111.35%
5Y Avg
101.76%
Market Cap
$200.54B
Return on Equity (ROE)
53.50%
TTM Avg
61.58%
3Y Avg
67.05%
5Y Avg
123.42%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | $439.68B | N/A | 132.52% | 70.84% | 62.85% |
| Merck & Co., Inc. (MRK)vs › | $366.74B | 7.57% | 35.83% | 26.05% | 27.71% |
| UnitedHealth Group Incorporated (UNH)vs › | $364.02B | 14.34% | 14.18% | 19.86% | 21.18% |
| Roche Holding AG (RHHBY)vs › | $344.74B | 38.06% | 32.06% | 36.93% | 40.66% |
| AstraZeneca PLC (AZN)vs › | $248.20B | 20.79% | 19.16% | 15.60% | 13.86% |
| Johnson & Johnson (JNJ)vs › | $648.55B | 24.76% | 26.27% | 31.76% | 29.75% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.09B | 13.25% | 12.70% | 13.51% | 15.24% |
| Amgen Inc. (AMGN)vs › | $212.20B | 74.80% | 79.33% | 111.35% | 101.76% |
| Novo Nordisk A/S (NVO)vs › | $200.54B | 53.50% | 61.58% | 67.05% | 123.42% |
| Abbott Laboratories (ABT)vs › | $182.59B | 10.61% | 20.32% | 18.59% | 17.97% |
ROE
N/A
ROA
4.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-03-31 | 295.42% |
| 2024-12-31 | 128.66% |
| 2024-09-30 | 84.91% |
| 2024-06-30 | 78.77% |
| 2024-03-31 | 74.85% |
| 2023-12-31 | 46.94% |
| 2023-09-30 | 53.86% |
| 2023-06-30 | 67.50% |
| 2023-03-31 | 57.14% |
| 2022-12-31 | 68.60% |
| 2022-09-30 | 83.83% |
| 2022-06-30 | 86.24% |
| 2022-03-31 | 76.64% |
| 2021-12-31 | 74.91% |
| 2021-09-30 | 55.60% |
| 2021-06-30 | 53.01% |
| 2021-03-31 | 37.63% |
| 2020-12-31 | 35.30% |
| 2020-09-30 | 48.34% |
| 2020-06-30 | 47.30% |
| 2018-03-31 | 179.59% |
| 2017-12-31 | 104.16% |
| 2017-09-30 | 99.42% |
| 2017-06-30 | 110.08% |
| 2017-03-31 | 126.25% |
| 2016-12-31 | 128.41% |
| 2016-09-30 | 93.97% |
| 2016-06-30 | 101.42% |
| 2016-03-31 | 117.94% |
| 2015-12-31 | 130.39% |
| 2015-09-30 | 57.93% |
| 2015-06-30 | 37.86% |
| 2015-03-31 | 131.88% |
| 2014-12-31 | 101.84% |
| 2014-09-30 | 79.91% |
| 2014-06-30 | 79.92% |
| 2014-03-31 | 88.14% |
| 2013-12-31 | 91.90% |
| 2013-09-30 | 126.91% |
| 2013-06-30 | 145.04% |
| 2013-03-31 | 181.25% |
| 2012-12-31 | 156.84% |
| 2012-09-30 | 31.22% |
| 2012-06-30 | 28.86% |
| 2012-03-31 | 29.81% |
| 2011-12-31 | 28.77% |
